Journal of Crohn's & colitis · 2026
Risk and outcome of interstitial lung disease in inflammatory bowel disease: evidence from a Danish nationwide population-based cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baekdal Jonas A, Hansen Erik Sören Halvard, Meteran Howraman, Ulrik Charlotte Suppli, Bendtsen Flemming, Håkansson Kjell Erik Julius, Brustad Nicklas, Jacobsen Peter Ascanius, Burisch Johan, Bendstrup Elisabeth
Аннотация
BACKGROUND: Extra-intestinal manifestations of inflammatory bowel disease (IBD) are well-recognized, but the long-term risk of developing interstitial lung disease (ILD) in IBD and its impact on mortality remain poorly understood. We aimed to assess the risk of ILD in patients with IBD and the subsequent effect on survival.
METHODS: This nationwide cohort study (1978-2022) utilized the Danish National Patient Registry, including 53 591 patients with IBD and 267 955 age- and sex-matched controls. Adjusted hazard ratios (aHRs) were estimated using Cox regression, adjusted for age, sex, education, and Charlson Comorbidity Index (CCI). Cumulative incidence was assessed via the Aalen-Johansen estimator. Mortality in patients with comorbid IBD-ILD was analyzed using Cox regression and Kaplan-Meier curves.
RESULTS: The 45-year cumulative incidence of ILD was 2.1% for IBD versus 0.9% for controls (P < .001), and aHR was 2.1 (95% CI, 1.8-2.4). Furthermore, the aHR was 3.0 (95% CI, 2.2-4.1) in patients with frequent IBD-related hospitalizations compared to matched controls. The 5-year mortality in concomitant IBD and ILD was 29.3% (95% CI, 23.3-35.3) compared to 11.9% (95% CI, 9.8-14.0) for matched patients with only IBD. Male sex and higher CCI were independent risk factors for both ILD and mortality (all P < .001).
CONCLUSION: IBD is associated with a two-fold increase in ILD risk. Risk factors may include old age, longstanding disease, male sex, and comorbidity. Comorbid IBD-ILD increases mortality substantially compared to only IBD, highlighting the need for clinical awareness and early detection to improve outcomes.
METHODS: This nationwide cohort study (1978-2022) utilized the Danish National Patient Registry, including 53 591 patients with IBD and 267 955 age- and sex-matched controls. Adjusted hazard ratios (aHRs) were estimated using Cox regression, adjusted for age, sex, education, and Charlson Comorbidity Index (CCI). Cumulative incidence was assessed via the Aalen-Johansen estimator. Mortality in patients with comorbid IBD-ILD was analyzed using Cox regression and Kaplan-Meier curves.
RESULTS: The 45-year cumulative incidence of ILD was 2.1% for IBD versus 0.9% for controls (P < .001), and aHR was 2.1 (95% CI, 1.8-2.4). Furthermore, the aHR was 3.0 (95% CI, 2.2-4.1) in patients with frequent IBD-related hospitalizations compared to matched controls. The 5-year mortality in concomitant IBD and ILD was 29.3% (95% CI, 23.3-35.3) compared to 11.9% (95% CI, 9.8-14.0) for matched patients with only IBD. Male sex and higher CCI were independent risk factors for both ILD and mortality (all P < .001).
CONCLUSION: IBD is associated with a two-fold increase in ILD risk. Risk factors may include old age, longstanding disease, male sex, and comorbidity. Comorbid IBD-ILD increases mortality substantially compared to only IBD, highlighting the need for clinical awareness and early detection to improve outcomes.